The role of 18F-FDG-PET/CT as an index staging tool has been validated for oesophageal cancer in guiding treatment. Patients with locoregionally advanced disease undergo neoadjuvant chemoradiotherapy, and re-staging interim FDG-PET/CT prior to oesophagectomy. The utility of the interim scan remains controversial as current literature reports mixed findings in its predictive potential. We aim to evaluate the predictive value of interim FDG-PET/CT in an Australian population. This is a retrospective cohort analysis for patients with locoregionally advanced oesophageal cancer (T3+, N0/1+, M0) from 2018 to 2023 at a tertiary hospital. All patients received a staging FDG-PET/CT and underwent neoadjuvant therapy with chemoradiotherapy. An interim FDG-PET/CT was performed post neoadjuvant therapy. Interval changes of SUVmax (g/mL) between the index and interim FDG-PET/CT were measured for primary and nodal lesions. The degree of radiological response to neoadjuvant therapy was categorized with the PERCIST response criteria. Pathological tumour response was measured with Mandard Score, from oesophagectomy specimen. STATA-18 was used for statistical analysis. Ordinal regression analysis was performed to measure the relation between radiological and pathological response. Kaplan-Meir curves and Cox regression were used for recurrence analysis. In our cohort of 61 patients, radiological response in SUVmax did not significantly predict pathological response from neoadjuvant therapy. Of the 42 patients with 24-month follow-up, good radiological response did not demonstrate lower recurrence rate on our survival analysis. We noted that high index SUVmax was associated with poorer outcomes. In conclusion, interim FDG-PET/CT does not appear to offer prognostic value.